The ASX 200 (Index: ^AXJO) (ASX: XJO) was eventful again this week. Here are four big stories you may have missed that affected businesses in the ASX 200 index:
Commonwealth Bank of Australia's (ASX: CBA) CommInsure criminal proceedings
CBA's insurance division is facing criminal proceedings by the Director of Public Prosecutions (DPP) with 87 alleged contraventions of the anti-hawking provisions.
According to CBA, the alleged contraventions relate to telephone sales of Simple Life insurance products by CMLA in the period from 7 October 2014 to 16 December 2014, a practice that ceased at the end of 2014.
This is probably some of the matters that were being investigated arising from the royal commission.
Magellan Financial Group Ltd's (ASX: MFG) large new trust
The investment fund manager has been raising money for its new listed investment trust called the Magellan High Conviction Trust.
This week Magellan said that it raised $862 million from investors. The estimated costs of the offer that will be paid by it, inclusive of loyalty units and IPO foundation units, are approximately $55 million.
National Australia Bank Ltd (ASX: NAB) royal commission costs
It was a hard week to be a shareholder of NAB after the large bank announced a very large remediation cost this week.
The bank announced additional charges of $1,180 million after tax ($1,683 million before tax) relating to increased provisions for customer-related remediation and a change to the application of its software capitalisation policy, charges of $832 million after tax ($1,189 million before tax) relate to additional customer-related remediation.
Will this hit the final FY19 dividend? We'll have to wait and see.
Mayne Pharma Group Ltd (ASX: MYX) agreement
Mayne Pharma has signed a 20-year exclusive supply and license agreement with Mithra Pharmaceuticals to commercialise a novel oral contraceptive in the United States.
The peak net sales potential could exceed US$200 million per annum, so it could be very lucrative for Mayne Pharma.
However, the deal could cost Mayne almost 10% of its shares as well as cash. Despite that, the Mayne share price is still up around 10%.
